BioPharma Resources

Drug Trial Radar · NCT07219407

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Feb 3, 2028

Study completion Feb 3, 2028

Sponsor

Lead sponsor
Rapport Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

Conditions

  • Focal Epilepsy
  • Epilepsy
  • Refractory Focal Epilepsy
  • Seizure
  • Focal Seizure
  • Focal Onset Seizure

Interventions

  • RAP-219Drug

    Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From the start of RAP-219 treatment through 8 weeks after last dose, up to Week 112

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Study Center

    Boise, Idaho · Recruiting

  • Clinical Study Center

    Rochester, Minnesota · Recruiting

  • Clinical Study Center

    New York, New York · Recruiting

  • Clinical Study Center

    Cleveland, Ohio · Recruiting

  • Clinical Study Center

    Philadelphia, Pennsylvania · Recruiting

  • Clinical Study Center

    Nashville, Tennessee · Recruiting

  • Clinical Study Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.